Compare COYA & ERH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COYA | ERH |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 107.4M |
| IPO Year | 2022 | N/A |
| Metric | COYA | ERH |
|---|---|---|
| Price | $4.28 | $12.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $15.80 | N/A |
| AVG Volume (30 Days) | ★ 266.7K | 28.5K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.85% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,945,753.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $763.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.57 | N/A |
| 52 Week Low | $3.71 | $11.50 |
| 52 Week High | $7.75 | $13.07 |
| Indicator | COYA | ERH |
|---|---|---|
| Relative Strength Index (RSI) | 33.98 | 44.88 |
| Support Level | $3.90 | $11.58 |
| Resistance Level | $5.18 | $12.02 |
| Average True Range (ATR) | 0.34 | 0.19 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 2.99 | 37.84 |
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.